Skip to main content

Advertisement

Log in

A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody

  • Case Report
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Multicentric Castleman's disease (MCD) is a rare systemic lymphoproliferative disorder with too few patient series reported in the literature to have a clear idea about the etiology, outcome and the best treatment available. Systemic reactive amyloidosis is a very rare complication of MCD and its presence worsens the prognosis. We report a case of a 28-year-old patient with plasma-cell type, human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative MCD who responded to treatment with chemotherapy and the anti-CD20 monoclonal antibody, rituximab. Anti-CD20 therapy could be an interesting adjunctive treatment in MCD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Keller A, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683

    CAS  PubMed  Google Scholar 

  2. Flendrig J, Schillings PHM (1969) Benign giant lymphoma: the clinical signs and symptoms. Folia Med Neerl 12:119

    Google Scholar 

  3. Peterson B, Frizzera G (1993) Multicentric Castleman's disease. Semin Oncol 20:636–647

    CAS  PubMed  Google Scholar 

  4. Chronowski G, Ha C, Wilder R et al (2001) Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 92:670–676

    Article  CAS  PubMed  Google Scholar 

  5. Katano H, Sata T (1999) An attractive relation of human herpesvirus-8 with multicentric Castleman's disease. Intern Med 38:221–222

    CAS  PubMed  Google Scholar 

  6. Hayashi M, Aoshiba K, Shimada M et al (1999) Kaposi's sarcoma-associated herpesvirus infection in the lung in multicentric Castleman's disease. Intern Med 38:279–282

    CAS  PubMed  Google Scholar 

  7. Bowne W, Lewis J, Filippa D, et al (1999) The management of unicentric and multicentric Castleman's disease. Cancer 85:706–717

    CAS  PubMed  Google Scholar 

  8. Andres E, Maloisel F (2000) Interferon-α as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol 11:1613–1614

    Article  CAS  PubMed  Google Scholar 

  9. Rieu P, Droz D, Gessain A et al (1999) Retinoic acid for treatment of multicentric Castleman's disease. Lancet 354:1262–1263

    Article  CAS  PubMed  Google Scholar 

  10. Nishimoto N, Sasai M, Shima Y, Nakagawa M et al (2000) Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56–61

    CAS  PubMed  Google Scholar 

  11. Corbellino M, Bestetti G, Scalamogna C et al (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 12:3473–3475

    Article  Google Scholar 

  12. Suda T, Katano H, Delsol G, Kakiuchi C, Nakamura T et al (2001) HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int 51:671–679

    Article  CAS  PubMed  Google Scholar 

  13. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M et al (2002) Update on Kaposi's sarcoma and other HHV-8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2:344–352

    Article  PubMed  Google Scholar 

  14. West KP, Morgan DR, Lauder I (1989) Angiofollicular lymph node hyperplasia with amyloidosis. Postgrad Med J 65:108–111

    CAS  PubMed  Google Scholar 

  15. Ordi J, Grau JM, Junque A, Nomdeleu B, Palacin A, Cardesa A (1993) Secondary (AA) amyloidosis associated with Castleman's disease. Am J Clin Pathol 100:394–397

    CAS  PubMed  Google Scholar 

  16. Miura A, Saro I, Suzuki C (1995) Fatal diarrhea in a patient with Castleman's disease associated with intestinal amyloidosis. Intern Med 34:1106–1109

    CAS  PubMed  Google Scholar 

  17. Tanaka K, Horita M, Shibayama H, Seike M, Itoh Y et al (1995) Secondary amyloidosis associated with Castleman's disease. Intern Med 34:122–126

    CAS  PubMed  Google Scholar 

  18. Funabiki K, Kaneko S, Terajima M, Tomita H, Kawano Y, Tomino Y (1998) A case of multicentric Castleman's disease associated with renal amyloidosis and pure red cell aplasia. Am J Nephrol 18:247–250

    CAS  PubMed  Google Scholar 

  19. Altiparmak MR, Pamuk GE, Pamuk ON, Dogusoy G (2002) Secondary amyloidosis in Castleman's disease: review of the literature and report of a case. Ann Hematol 81:336–339

    Article  CAS  PubMed  Google Scholar 

  20. Derici U, Arinsoy T, Ataoglu O, Bali M, Sindel S et al (2002) Localized Castleman's disease and nephrotic syndrome not responsive to resection plus colchicine therapy. Ann Hematol 81:399–401

    Article  CAS  PubMed  Google Scholar 

  21. Sezer O, Eucker J, Schmid P, Possinger K (2000) New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol 79:1-6

    Article  CAS  PubMed  Google Scholar 

  22. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA (1999) Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 17:262–267

    CAS  PubMed  Google Scholar 

  23. Van Eygen K, Zachee P, Maertens J, Vandenberghe P, Demuynck H, Verhoef G, Boogaerts A (1996) Treatment of primary amyloidosis with VAD combination chemotherapy results in improved survival. Blood 88(1):591a

    Google Scholar 

  24. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone and melaphalan, prednisone and colchicine. N Engl J Med 336:1202–1207

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Ms. Lorna Saint Ange for editing.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dany Gholam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gholam, D., Vantelon, JM., Al-Jijakli, A. et al. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol 82, 766–768 (2003). https://doi.org/10.1007/s00277-003-0718-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-003-0718-x

Keywords

Navigation